AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker to put its US shares on par with its London-based stock, but says HQ will stay in Cambridge

GSK’s Emma Walmsley to be replaced as CEO

Business live – latest updates

The UK’s biggest drugmaker, AstraZeneca, has said it will list its shares directly on the New York Stock Exchange in a decision described a “knock-back for London”.

The FTSE 100 company said its direct listing in New York would replace trading in its American depositary receipts (ADRs) – which give US investors exposure to a non-US company – on the Nasdaq.